Advertisement

Topics

M&As this week: Nabriva Therapeutics, Sangamo Therapeutics, Ryboquin

19:00 EDT 26 Jul 2018 | Net Resources International

Nabriva Therapeutics has completed the acquisition of Zavante Therapeutics for $97.5m. The acquisition will add the target company’s CONTEPO™ drug, which...
Read More...

The post M&As this week: Nabriva Therapeutics, Sangamo Therapeutics, Ryboquin appeared first on Drug Development Technology.

Original Article: M&As this week: Nabriva Therapeutics, Sangamo Therapeutics, Ryboquin

NEXT ARTICLE

More From BioPortfolio on "M&As this week: Nabriva Therapeutics, Sangamo Therapeutics, Ryboquin"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Mergers & Acquisitions
Commercial and market reports on mergers and acquisitions in the biotechnology, pharmaceutical, medical device and life-science industries. Mergers and acquisitions (abbreviated M&A;) is an aspect of corporate strategy, corporate finance and manageme...

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...